Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics (eniluracil, STS, ADH-1).
Going Concern: The filing includes a substantial doubt disclosure regarding the company's ability to continue as a going concern due to an accumulated deficit of $102.2 million and a history of negative cash flows from operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Income (Loss) | $1,694 | $(1,240) | N/A |
| Operating Expenses | $917 | $3,788 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $6,602 |
| Total Assets | N/A | N/A | $6,603 |
| Total Liabilities | N/A | N/A | $4,998 |
| Stockholders' Equity | N/A | N/A | $1,605 |
| Accumulated Deficit | N/A | N/A | $(102,231) |
Key Drivers: The net income for the three-month period was driven primarily by a non-cash unrealized gain of $2.57 million on derivative warrant liabilities. Operating cash flow for the nine months ended September 30, 2010, was negative $1.27 million.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased from $685,000 at December 31, 2009, to $6.6 million at September 30, 2010. This was primarily due to a private placement completed in April 2010 yielding net proceeds of $7.2 million.
- Derivative Liability: A new long-term liability of $4.69 million was recorded for derivative warrants issued in the April 2010 financing. These warrants are denominated in Canadian dollars while the company's functional currency is USD, requiring fair value accounting as a liability.
- Operating Expenses: Total operating expenses for the nine months ended September 30, 2010, were $3.8 million, an increase of $0.5 million compared to the prior year period. This increase was largely due to higher stock-based compensation ($2.4 million vs. $0.5 million in 2009), partially offset by reduced clinical development costs.
- Net Loss Reduction: The net loss for the nine months ended September 30, 2010, was $1.24 million, a significant improvement from the $3.22 million loss in the same period in 2009, largely due to the unrealized gain on derivatives.
Outlook, Risks, and Contingencies
- Capital Needs: Management states the company will need to obtain additional funding to finance business strategy and operations. Failure to secure capital may require curtailing business activities.
- Proposed Rights Offering: On November 12, 2010, the company filed a registration statement for a proposed rights offering to raise up to CAD$12.75 million (gross) to fund the Phase II clinical trial of eniluracil and general corporate purposes.
- Clinical Pipeline:
- Eniluracil: Planning a Phase II study in metastatic breast cancer in Russia (in collaboration with OCT Group LLC), expected to commence within six months.
- STS: Continuing Phase III trials for pediatric liver cancer in collaboration with SIOPEL and the Children's Oncology Group.
- ADH-1: License agreement with McGill University terminated; company retains "method of use" patents and supports an investigator-led Phase I study.
- Internal Control Weaknesses: Management identified two material weaknesses: lack of segregation of duties (one person performs all accounting duties) and insufficient personnel with technical accounting knowledge, leading to delayed filings.
- Listing Status: The company satisfied Toronto Stock Exchange listing requirements following a review in August 2010, though it remains a "penny stock" subject to trading restrictions.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $6.6 million cash balance against the projected costs of the upcoming Phase II eniluracil trial and general operating expenses.
- Derivative Liability Volatility: Monitor the fair value of the $4.7 million warrant liability, as fluctuations in the stock price and exchange rates will create significant non-cash gains or losses impacting net income.
- Financing Execution: Confirm the effectiveness of the November 2010 registration statement for the proposed rights offering and the actual proceeds raised.
- Internal Controls: Assess the company's progress in remediating the identified material weaknesses in financial reporting and segregation of duties.
- Clinical Milestones: Track the commencement and enrollment status of the eniluracil Phase II trial in Russia and the STS Phase III trials.